
TVS launches 2025 Apache RTR 310 with smart features, starting at Rs 2.39 lakh
TVS Motor Company has officially launched the 2025 Apache RTR 310 in India, and it's turning heads with its new-age tech, performance updates, and aggressive design. Starting at ₹2.39 lakh (ex-showroom), this streetfighter has been designed to offer a smarter, more connected, and customizable riding experience for today's enthusiasts.
Backed by TVS's four-decade racing legacy, the new RTR 310 isn't just about looks—it's all about precision and performance. The bike is now OBD2B-compliant, meaning it can monitor emissions in real time and keep your engine in top shape.
One of the biggest highlights? A fresh new Gen-2 digital cluster with a multi-language interface, giving riders a more personalized and immersive ride experience. And yes, there are plenty of cool new features too—like hand guards, USD front suspension, a transparent clutch cover, and sequential turn indicators.
TVS continues to offer its factory customization platform, Built-To-Order (BTO), which now includes features like Keyless Ride, Drag Torque Control, and even Launch Control—firsts in this segment.
Powering the machine is a 312.2cc engine delivering 35.6 PS and 28.7 Nm of torque, promising a punchy and agile ride. Riders can choose from five variants, including three BTO versions. Prices are as follows: Base Variant: ₹2,39,990
Top Variant: ₹2,57,000
BTO Variant: From ₹2,75,000
The 2025 Apache RTR 310 is now available across major cities, including Delhi, Mumbai, Bengaluru, Chennai, and Kolkata. Whether you're a city rider or weekend warrior, this updated Apache is built to thrill.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Upturn
7 hours ago
- Business Upturn
Nibe signs Technical Collaboration Agreement with Israel's Elbit Systems for PULS rocket system
Nibe Limited has officially entered into a technical collaboration agreement with Israel-based defence technology firm Elbit Systems Land Limited. Signed on July 26, 2025, the agreement focuses on the transfer of license and technology for the Precise & Universal Launch System (PULS), a high-range artillery rocket system. Under this agreement, Elbit will provide Nibe with the necessary know-how and licensing rights to manufacture and assemble the PULS system in India. The system is designed for long-range precision targeting, capable of engaging threats at distances up to 300 kilometers. The collaboration aims to establish a local manufacturing setup for PULS in India, allowing Nibe to take on responsibilities for development, assembly, and integration. The financial terms of the agreement are expected to be finalized within 45 days from the signing date. This is a purely international partnership between two independent entities, with no related party transaction involved. Neither Nibe's promoter group nor its affiliates have any stake or interest in Elbit Systems Land Limited. The agreement aligns with the regulatory requirements under SEBI's disclosure norms. With this development, Nibe Limited expands its presence in the defence manufacturing sector by bringing advanced rocket system capabilities to the domestic market through technology collaboration with a global player. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Upturn
10 hours ago
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Upturn
11 hours ago
- Business Upturn
Nifty top gainers this week (July 26): Eternal, ICICI Bank, Cipla, HDFC Life, Hindalco Industries and more
By Aman Shukla Published on July 26, 2025, 09:45 IST The Indian stock market wrapped up the week ending July 26, 2025, deep in negative territory, extending its losing streak to a fourth consecutive week — the longest such stretch this year and the first since October 2024. Both benchmark indices — BSE Sensex and Nifty 50 — declined by around 0.5% over the week, weighed down by broader market weakness. The Nifty Midcap 100 dropped 1.5%, significantly underperforming the large-cap peers. However, there was a slight silver lining: Nifty Bank bucked the trend and managed a marginal 0.5% gain. Despite the bearish close to the week, several heavyweight stocks in the Nifty 50 index delivered notable weekly gains. Let's take a closer look at the top 10 losers of the Nifty 50 this week, according to Trendlyne. Eternal — up 20.7% this week, closing at ₹310.6 ICICI Bank — up 3.6% this week, closing at ₹1,477.1 Cipla — up 3.4% this week, closing at ₹1,532.5 HDFC Life Insurance — up 3.1% this week, closing at ₹762.4 Hindalco Industries — up 2.6% this week, closing at ₹693.5 SBI Life Insurance — up 2.4% this week, closing at ₹1,832.1 HDFC Bank — up 2.4% this week, closing at ₹2,004.6 Apollo Hospitals — up 2.3% this week, closing at ₹7,468.5 Bharti Airtel — up 1.9% this week, closing at ₹1,937.9 Titan Company — up 1.8% this week, closing at ₹3,462.8 Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash CiplaEternalHDFC LifeHindalco IndustriesICICI BankStock Market Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at